Blockchain-Based Pharmacovigilance Framework: Enhancing Drug Safety Through Distributed Ledger Technology

Jiaxuan Wei [1, a, *], Yue Cai [2, b], and Jiaying Tao [3, c]

[1] School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210000, China;

[2] School of Pharmacy, Nanjing University of Chinese Medicine, Changzhou, 213000, China;

[3] First School of Clinical Medicine, Nanjing University of Chinese Medicine, Changzhou, 213000, China.

[a] 17368687371@163.com, [b] 15961214300@163.com, [c] 976009837@qq.com

Abstract. The study proposes a blockchain-based framework to overcome the challenges of data silos, privacy risks, and interoperability limitations in pharmacovigilance systems, focusing on the refinement of adverse drug reaction (ADR) data collection, storage, and analysis. Incorporating blockchain's transparency, immutability, and security, the framework comprises four core components: a data collection layer for multi-source ADR reporting, a standardization layer for data integration and validation, a blockchain network layer for tamper-proof storage and secure sharing, and a data analysis layer for real-time risk detection and visualization. The framework's efficacy in drug safety monitoring and regulatory efficiency is exemplified by the MediLedger and Merck's SAP Pharma Blockchain Proof of Concept case studies. The proposed resolution shows remarkable potential for advancing global pharmacovigilance practices.

Keywords: Blockchain, pharmacovigilance, adverse drug reaction, drug safety, distributed ledger technology.

1. Introduction

Pharmacovigilance is essential for monitoring and preventing adverse drug reactions (ADR). As the global pharmaceutical market expands, traditional systems—reliant on fragmented databases—struggle with data silos, privacy risks, and inefficient integration. Blockchain, a decentralized and tamper-proof ledger, addresses these challenges by enabling secure cross-institutional data sharing. Each block cryptographically links to prior records, ensuring traceability and consistency through consensus mechanisms. Pharmacovigilance is confronted with dual challenges of insufficient data sharing/integration and inadequate privacy/security safeguards, jeopardizing work efficiency, quality, and patient medication safety. In light of the aforementioned challenges, we propose a blockchain-based pharmacovigilance framework.

2. Background

2.1 Current Status of Pharmacovigilance

In 2002, World Health Organization gave a specific definition of pharmacovigilance, which is the activities and science of discovering, evaluating, understanding, and preventing ADR or other drug-related problems(https://www.who.int/publications/i/item/10665-42493). With the proposal of pharmacovigilance, the attention paid to it at home and in abroad has been increasing. On November 29th, 2007, China held the first China Pharmacovigilance Symposium, proposing to establish a pharmacovigilance system based on the existing adverse drug reaction monitoring system. In the “14th Five-Year Plan”, China has clearly regarded the establishment of a pharmacovigilance system, covering the entire life cycle of drugs as a key task to ensure the safety of patients' medication [1]. The pharmacovigilance system of developed countries such as Europe and the United States is relatively mature, and its regulatory system, organizational structure, and technical support system are relatively complete [2]. These countries have set up active testing programs to strengthen the safety warning and guarantee of drugs by collecting data from different institutions [3].

In 2014, the European Union Innovative Drugs Initiative joined hands with WHO and the Uppsala Monitoring Center to launch a project that allows medical workers and patients to report adverse drug reactions directly through the Internet [4]. The project was run as a pilot in the United Kingdom, the Netherlands, and Croatia, resulting in the broadening of the reporting channels and a notable increase in the reporting rate of adverse drug reactions.

2.2 Main Challenges of Pharmacovigilance

Although the importance of pharmacovigilance is increasing on a global level, it is met with various challenges that impact its efficiency and quality and might put the safety of patients' medication at risk.

2.2.1 Lack of Correlation between Data Sharing and Integration

In the field of pharmacovigilance, sharing and integrating data between disparate institutions and systems is challenging, resulting in a significant "information island" issue. Gartner's 2022 medical data analysis report indicates that approximately 60% of medical institutions globally have data silos, and the integration rate of pharmacovigilance data with other medical systems, such as electronic health records and laboratory systems, is below 20%. These "information islands" not only squander valuable data resources but may also lead to the omission and misjudgment of critical information, impacting the safety of patient medication.

2.2.2 Hidden Dangers in Data Privacy and Security

The traditional pharmacovigilance system faces numerous challenges in data privacy and security, hindering its ability to fulfill the requirements of contemporary pharmacovigilance tasks. Some systems are deficient in robust data encryption and access control protocols, thereby elevating the risk of data breaches and misuse. According to the Ponemon Institute's Global Healthcare Data Security Report 2023, the average cost of a single data breach within the healthcare industry amounts to $10.93 million, a figure 1.85 times greater than that of the financial sector. Pharmacovigilance data has emerged as a prime target for hacker incursions due to its inclusion of sensitive information such as patient genetic profiles and medication histories.

2.2.3 System Incompatibility and Data Standard Inconsistency

According to the statistics of the European Medicines Agency (EMA) in 2022, the difference in the reporting rate of adverse reactions to the same drug in different countries is more than 100%. This difference not only increases the difficulty and cost of data processing but also affects the accurate evaluation and timely control of adverse drug reactions.

2.2.4 The Difficulty of Processing Large-scale Data in Traditional Systems

As medical data grows exponentially and pharmacovigilance becomes increasingly complex, the traditional system is no longer sufficient for processing large-scale data and conducting real-time monitoring. According to IDC's Global Medical IT Trend Report 2023, the conventional pharmacovigilance system struggles to manage the daily average of 1 billion potential risk signals, which includes feedback from social media and e-commerce platforms. Furthermore, the system is deficient in real-time monitoring and early warning capabilities, making it challenging to promptly identify hidden drug safety risks.

2.2.5 Basic Principles of Blockchain Technology

Blockchain technology, introduced by Satoshi Nakamoto in 2008 [5] features decentralization [6], trustlessness, transaction irreversibility, and data immutability [7]. It addresses issues like the double-spending problem [8] through distributed ledger technology (DLT) [9] and consensus mechanisms. Operating as a decentralized network [10], blockchain enables direct peer-to-peer connections between devices without intermediaries. Nodes in the network maintain complete ledger copies, with transactions chronologically packed into chained blocks to form transparent, tamper-proof records. This makes it particularly valuable in pharmaceutical logistics, where pharmacovigilance demands high data authenticity, integrity, security, and traceability. Current challenges in pharmacovigilance include complex data sources, verification difficulties, cross-institutional sharing barriers, and compliance oversight [11]. Integrated with smart contracts, blockchain can optimize data management, enhance drug safety monitoring, and advance innovative "blockchain + pharmaceutical logistics" models [12], [13] (see Fig. 1)



Fig. 1. "blockchain + pharmaceutical logistics" models.

2.2.6 Integrating Efficient Data Management in Electronic Information Engineering

Automate ADR data processing via smart contracts to minimize manual intervention. Integrate edge computing with high-speed networks (e.g., 5G) to enable real-time analysis, alerts, and scalable data handling. By combining blockchain, encryption algorithms from electronic/information engineering, and distributed communication architectures, a secure, transparent, and efficient pharmacovigilance system can be established, aligning with the pharmaceutical industry's technical demands.

3. Proposed Framework

3.1 Architecture Overview

The proposed blockchain-based pharmacovigilance framework comprises four core modules designed to optimize the collection, storage, and analysis of adverse drug reaction (ADR) data by leveraging the transparency, immutability, and security features of blockchain technology. The framework architecture is illustrated in Fig. 2.



Fig. 2. Blockchain Pharmacovigilance Framework Design.

3.1.1 Data Collection Layer

The data collection layer gathers adverse drug reaction data from multiple sources, including hospitals, pharmacies, and patients. By integrating with hospital electronic health record (EHR) systems, it retrieves patient medication information, clinical data, and prescription details. Simultaneously, drug feedback and ADR reports from pharmacies, along with drug inventory and usage records, are incorporated into the dataset. Patients can directly report ADR incidents and medication feedback through mobile applications, ensuring comprehensive and timely data collection.

3.1.2 Data Standardization Layer

The standardization layer processes begin with the cleansing, integration and normalization of the raw data. Every data entry is validated for accuracy and standardization while duplicates, incorrect, and obsolete data is removed. Different forms are also transformed to a singular uniform style. All mapping techniques transform different datasets into one by crosschecking and merging data to create one cohesive dataset to guarantee consistency and validity within the newly formed dataset.

3.1.3 Blockchain Network Layer

In the blockchain network layer, the standardized data is stored using distributed ledger technology which increases transparency and immutability. Data at rest or in transit is secured through encryption techniques including symmetric and asymmetric encryption. Every single record is provided with a unique timestamp then tagged and replicated across multiple nodes.block consensus mechanisms like Proof of Work (PoW) or Proof of Stake (PoS) are employed to eliminate chances of inconsistent tampering across the nodes.

3.1.4 Data Analysis Layer

In the data analysis layer, the mining and visualization of block data is carried out. Analysis of trends and time series facilitates the detection of permanent changes and repeating periodic movements in the ADR data.Potential risks are assessed using risk evaluation models after unusual signals are captured using anomaly detection algorithms. Providing analytical results in interactive dashboards encourages the development of charts and reports for the use of healthcare institutions and other regulated authorities aiding in prompt decisional processes.

3.2 Rationale for Blockchain-Driven Pharmacovigilance

3.2.1 Ensuring Patient Medication Safety

Pharmacovigilance actively protects patients from the potentially dangerous effects that drugs may have, while monitoring their consumption. Blockchain technology secures ADR data, facilitating proper detection of drug safety threats and averting adverse events and consequential harm to patients. Blockchain sustains the authenticity and integrity of ADR data provision, enabling prompt detection of possible risks to patientssafety and averting injury from negative drug conditions or events.

3.2.2 Ensuring Patient Medication Safety

In pharmacovigilance, medication safety is well-practiced and easily maintained. Blockchain technology secures ADR data's authenticity and integrity supporting adverse event mid detection heedless of the conditions and aiding patients protective measures against these occurrences.

3.2.3 Enhancing Drug Regulatory Efficiency

Exchange of drug production, distribution, and usage information has been made easier in blockchain. Silo information gaps have been broken and data retrieval utility improved. Regulators are enabled access to real-time crucial data aids timely scrutiny precision and alert responsiveness highly geared improving performance quality. In frameworks dealing with blockchain-based pharmacovigilance, operational costs for pharmaceutical enterprises and regulatory bodies are greatly reduced by automated data processing [2], [4]. Equitable, clear, and veritable pharmaceuticals make up this spheres fostering sustainable foundation industry development.

4. Case Studies

4.1 MediLedger

With the help of renowned pharmaceutical companies, MediLedger was established in 2017. It is a blockchain-based endeavor aiming to monitor the movement of drugs throughout the supply chain using a permissioned blockchain network. That project improves the traceability of drugs, prevents counterfeit drugs from penetrating the market, and provides transparent verification for all stakeholders in the drug supply chain.

4.2 Merck & SAP's Drug Verification Application

SAP and Merck have worked together to create an application called SAP Pharma Blockchain POC for verifying the authenticity of the returned medications. Taking full advantage of blockchains advantages of decentralization and immutability, the application guarantees the full traceability of the returned medications, significantly reducing the prevalence of counterfeit drugs in the pharmaceutical supply chain.

5. Conclusion

This research shows that blockchain technology presents a feasible solution for enhancing pharmacovigilance systems. It does so by enhancing data integrity, transparency, and efficiency via its decentralized architecture, unalterable record - keeping, and secure data - sharing capabilities, as exemplified by successful cases like MediLedger and Merck's blockchain applications. Meanwhile, future work ought to concentrate on optimizing consensus mechanisms and integrating AI for proactive risk detection.

References

[1] Song H, Pei X, Liu Z, et al. Pharmacovigilance in China: evolution and future challenges[J]. British Journal of Clinical Pharmacology, 2023, 89(2): 510-522.

[2] Sagud M, Breznoscakova D, Celofiga A, et al. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance[J]. Schizophrenia Research, 2024, 268: 53-59.

[3] Bahk, Chi Y., et al. "Increasing patient engagement in pharmacovigilance through online community outreach and mobile reporting applications: an analysis of adverse event reporting for the Essure device in the US." Pharmaceutical medicine 29 (2015): 331-340.

[4] Shi, Wenhui, et al. "Comparative Study on Pharmacovigilance Signal Management System among the European Union, the United States and Japan." China Pharmacy (2021): 406-412.

[5] Nakamoto S, Bitcoin A. A peer-to-peer electronic cash system[J]. Bitcoin. – URL: https://bitcoin. org/bitcoin. pdf, 2008, 4(2): 15.

[6] You Jing, Luo Huiying. Research on the Service System and Key Business Processes of "Internet + Medical Health" Supported by Blockchain [J]. Digital Medicine, 2020, 15(7): 48-50.

[7] Abu-Elezz I, Hassan A, Nazeemudeen A, et al. The benefits and threats of blockchain technology in healthcare: A scoping review[J]. International Journal of Medical Informatics, 2020, 142: 104246.

[8] Research on Supply Chain Business Model Innovation Based on Blockchain Technology: A Case Study of the Pharmaceutical and Medical Industry [J]. Social Sciences and Management, Vol. 5, No. 2, July - December 2021, 2021, 5(2): 88.

[9] Abdennadher S, Cheffi W, Amin A H M, et al. Performance analysis of a blockchain process modeling: Application of distributed ledger technology in trading, clearing and settlement processes[J]. Journal of Open Innovation: Technology, Market, and Complexity, 2024, 10(3): 100348.

[10] Ahmadi V, Benjelloun S, El Kik M, et al. Drug governance: IoT-based blockchain implementation in the pharmaceutical supply chain[C]//2020 Sixth International conference on mobile and secure services (MobiSecServ). IEEE, 2020: 1-8.

[11] Chattu V K, Nanda A, Chattu S K, et al. The emerging role of blockchain technology applications in routine disease surveillance systems to strengthen global health security[J]. Big Data and Cognitive Computing, 2019, 3(2): 25.

[12] Signal Analysis in Pharmacovigilance: Principles and Processes[M]. CRC Press, 2024.

[13] Sun Y, Wang F, Zhuo X. Blockchain adoption of pharmaceutical firms in a competitive market: Pricing, drug traceability and consumer awareness[J]. International Journal of Production Economics, 2024, 276: 109356.